Introduction {#S0001}
============

The natural progression of atherosclerotic lesions has been described in many *in-vitro* and *in-vivo* studies. Studies have shown that changes in arterial intima-media thickness precede the formation of atherosclerotic plaques \[[@CIT0001], [@CIT0002]\]. These intima-media changes are known as subclinical atherosclerosis and can occur early in life without immediate clinical consequences. Non-invasive imaging modalities such as high-resolution magnetic resonance imaging (MRI), computed tomography (CT), and B-mode ultrasonography have been used to study longitudinal changes in atherosclerotic lesions and plaque morphology \[[@CIT0003]--[@CIT0005]\].

Carotid intima-media thickness (CIMT) measured by B-mode ultrasonography is a potentially useful non-invasive method of detecting subclinical atherosclerosis \[[@CIT0006]--[@CIT0009]\]. Compared to CT and MRI, B-mode ultrasound offers a low-cost and informative research tool, without ionizing radiation, for analyzing plaque composition and monitoring changes in its lipid content \[[@CIT0005], [@CIT0010]\]. In particular, vulnerable plaques, which are soft and lipid-rich, can be identified on ultrasound by their echo-lucent appearance \[[@CIT0005], [@CIT0006]\]. Therefore, ultrasonography provides a non-invasive method of studying subclinical atherosclerosis and vulnerable plaque in response to comprehensive interventions. However, there are certain limitations to the use of CIMT in the clinical setting. Despite earlier supportive studies, recent meta-analyses question the value of CIMT as an additional predictor of cardiovascular disease (CVD) risk \[[@CIT0011]--[@CIT0020]\]. It received a class III recommendation from the 2013 ACC/AHA lipid guidelines and is not recommended for use as a clinical marker for CVD risk \[[@CIT0021]\]. As a research tool, ultrasonography provides a non-invasive and cost-effective method of changes in plaque morphology and CIMT.

Lipid-modifying therapy helps form the core of modern clinical interventions to alter progression of atherosclerotic lesions. However, combination lipid therapy is controversial as several clinical trials have had mixed results (VA-HIT, HATS, and Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes (AIM-HIGH)) \[[@CIT0022]--[@CIT0024]\]. The difference in outcomes may be explained in part by the variable effects of lipid-lowering therapies on subclinical atherosclerosis and differences in the populations studied. The direct effect of statins and niacin on subclinical atherosclerosis was investigated by several CIMT studies, which found that in low-intermediate risk individuals, statins and niacin were effective in slowing or reversing CIMT progression \[[@CIT0025]--[@CIT0031]\]. Aggressive short-term statin therapy has also been shown to promote delipidation and stabilization of vulnerable plaque \[[@CIT0032], [@CIT0033]\]. These favorable changes in plaque morphology were observed using high-resolution optical coherence tomography and integrated backscatter intravascular ultrasound imaging \[[@CIT0034]\].

Longitudinal ultrasound CIMT and plaque morphology investigation offers a non-invasive and effective method to examine this progression. The goal of this retrospective study is to evaluate changes in CIMT and plaque morphology in a community cohort of patients receiving comprehensive CVD risk factor management.

Material and methods {#S0002}
====================

Demographics {#S20003}
------------

The study is a retrospective cohort of 324 patients participating in a comprehensive CVD risk factor management program from 2003 to 2008 in a community-based primary care clinic in the state of Washington. Out of 448 patients in this clinic (Spokane, Washington), 324 elected to participate in this program. There were no eligibility criteria, and patients were not stratified based on CVD risk. All participants underwent baseline and annual physical and laboratory examinations and CIMT scans. This analysis was based on available data collected from program participants. The primary data collection team received institutional review board exemption from the Texas Tech University Health Sciences Center. The data analysis team received institutional review board exemption from the Johns Hopkins School of Medicine. Informed consent was not obtained from study participants for their clinical records to be used in this study. Patient records were anonymized and de-identified prior to analysis.

Treatment strategy {#S20004}
------------------

All patients received extensive behavioral, dietary and lifestyle counseling in keeping with accepted guideline practice \[[@CIT0035], [@CIT0036]\]. Clinicians reviewed laboratory data and CIMT imaging, and treated patients with statin, statin plus niacin, statin plus ezetimibe, or statin plus niacin and ezetimibe. Statin-intolerant patients were treated with ezetimibe plus niacin \[[@CIT0037]\]. Retrospective grouping was based on their medication treatment ([Table I](#T0001){ref-type="table"}). Additional therapy with fibrates, bile acid sequestrants, and fish oils was also used as needed to achieve the more aggressive National Cholesterol Education Program (NCEP) ATP III lipid goals. Patients with a history of coronary artery disease (CAD) and/or hypertension were treated with standard low-dose aspirin 81 mg, angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker, β-blocker, diuretic, renin inhibitor, and/or clopidogrel as indicated. Patients with newly diagnosed insulin resistance, metabolic syndrome, and diabetes mellitus were started on oral insulin sensitizing agents, primarily metformin and thiazolidinediones.

###### 

Demographic characteristics and medication usage by treatment group at baseline

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                     Statin       Statin plus niacin   Statin plus ezetimibe   Statin plus niacin and ezetimibe   Niacin only   Ezetimibe only   All          *P*-value
  ----------------------------- ------------ -------------------- ----------------------- ---------------------------------- ------------- ---------------- ------------ -----------
  *N* (%)                       62 (14)      170 (38)             17 (4)                  55(12)                             17 (4)        3 (1)            324 (100)    

  Age, mean ± SD                56 ±11       56 ±9                54 ±9                   56 ±9                              50 ±13        61 ±4            56 ±10       0.129

  Female, *n* (%)               29 (48)      61 (36)              10 (59)                 17 (31)                            7 (41)        2 (67)           126 (39)     0.169

  CAD, *n* (%)                  0 (0)        20 (12)              3 (21)                  16 (31)                            1 (7)         0 (0)            40 (13)      \< 0.001

  Diabetes, *n* (%)             0 (0)        7 (5)                2 (15)                  5 (10)                             0 (0)         0 (0)            14 (5)       0.101

  Smoker, *n* (%)               18 (31)      50 (30)              7 (44)                  21 (38)                            3 (20)        0 (0)            99 (32)      0.451

  Hemoglobin A~1c~, mean ± SD   5.6 ±0.4     5.6 ±0.6             5.7 ±0.5                5.8 ±0.6                           5.2 ±0.4      5.4 ±0           5.5 ±0.7     0.103

  hs-CRP, median (IQR)          1.7\         1.1\                 1.0\                    0.6\                               1.5\          1.5\             1.1\         0.543
                                (0.6--2.6)   (0.6--2.2)           (0.4--1.8)              (0.5--1.6)                         (0.8--2.6)    (0.5--2.5)       (0.5--2.1)   

  ACEi use, *n* (%)             19 (31)      63 (37)              7 (41)                  24 (44)                            6 (35)        2 (67)           121 (37)     0.644
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Clinical and laboratory data {#S20005}
----------------------------

Baseline data included age, sex, height, weight, hemoglobin A~1c~ (HbA~1c~), high sensitivity C-reactive protein (CRP), and history of CAD, diabetes, or cigarette smoking. Body mass index (BMI) was not routinely measured, and baseline insulin use was not available. Blood pressure measurements and laboratory lipid samples were collected within 6 months of the annual CIMT scan and annually thereafter. Total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides were directly measured. Non-high-density lipoprotein cholesterol (non-HDL-C) was calculated as the difference between total cholesterol and HDL-C, while estimated low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald equation \[[@CIT0038]\]. Baseline HbA~1c~ was collected for all study participants. During the 5-year follow-up, 1131 HbA~1c~ measurements were obtained out of the 1548 follow-up data points. Baseline high-sensitivity C-reactive protein (hs-CRP) was collected for 471 out of 571 study participants. During the 5-year follow-up, 1303 hs-CRP measurements were obtained out of the 1548 follow-up data points.

B-mode ultrasound imaging {#S20006}
-------------------------

Certified sonographers at CardioRisk laboratories (South Jordan, UT) performed all annual CIMT scans. CIMT examinations were performed using Sonosite Titan systems equipped with high-resolution B-mode ultrasound with 10-5 MHz, 38-mm linear array transducers (Sonosite Inc, Bothell, WA).

CIMT measurements were obtained using well-defined anatomic markers in the distal 1 cm of the common carotid artery, the carotid bifurcation, and the proximal 1 cm of the internal carotid artery \[[@CIT0039]\]. On average, 800 measurements were made at each anatomic carotid site using edge-detection software included with the Sonosite Titan systems. Mean CIMT was the average of all measurements, and max CIMT was the average of the 6 thickest CIMT measurements (including regions with plaque). Carotid plaque was defined as a focal lesion at least 1.3 mm at its thickest point. Plaques were classified into three echo-density categories representing lipid-rich (echo-lucent), heterogeneous, and calcified (echo-dense) plaque. Plaque burden was the sum of the maximum thickness in each of the three measurement sites bilaterally.

Data collection {#S20007}
---------------

Research assistants collected data from clinic charts and removed patient identifiers. A data spreadsheet was generated, and a separate data analysis team reviewed the data to ensure integrity. Any missing or mistyped values were flagged and sent back to the data collection team for reexamination. After corrections were made, the database was locked for analysis.

Data analysis {#S20008}
-------------

Patients were retrospectively categorized into lipid treatment groups: statin only, niacin only, ezetimibe only, statin plus niacin, statin plus ezetimibe, statin plus niacin and ezetimibe. The dates of the annual CIMT study served as the primary analysis time point, and clinical and laboratory data obtained within 6 months of that CIMT measurement were attributed to that date.

Statistical analysis {#S20009}
--------------------

We examined the outcome measures of mean and max CIMT and plaque composition. Statistical analyses were performed using ANOVA, χ^2^ test, Fisher\'s exact, or median test, with *p*-values generated by the Wald test as appropriate. Analyses were performed on mean, max, and max minus mean (max--mean) CIMT, and plaque type (soft, heterogeneous and calcified). Changes in CIMT were evaluated using multilevel mixed-effects linear or logistic regression models with a patient-level random intercept. Patients lost to follow-up were censored at the last CIMT scan and were not adjusted for missing data bias.

Results {#S0010}
=======

Patient baseline results {#S20011}
------------------------

The study population included 324 Caucasian patients with at least two CIMT scans. Baseline demographic comparisons are shown in [Table I](#T0001){ref-type="table"}. Briefly, the study population had a mean age of 55 years, 39% were female, 13% had CAD, 5% had diabetes, and 32% were current or former smokers. The median time to the last CIMT was 3.0 years with a follow-up of 280 (86%), 234 (72%), 167 (52%), 85 (26%), and 20 (6%) patients at each of the first 5 years ([Table II](#T0002){ref-type="table"}).

###### 

Modifiable clinical risk factors over follow-up

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                      Year    *P*-value (first year)   *P*-value (after first year)                                   
  ---------------------------------------------- ------- ------------------------ ------------------------------ ------ ------ ------ ---------- ----------
  *N* (%)                                        324\    280\                     234\                           167\   85\    20\               
                                                 (100)   (86)                     (72)                           (52)   (26)   (6)               

  Non-HDL-C, mean ± SD \[mg/dl\]                 143\    107\                     106\                           105\   102\   102\   \< 0.001   0.835
                                                 ±41     ±33                      ±29                            ±32    ±31    ±29               

  LDL-C, mean ± SD \[mg/dl\]                     118\    89\                      89\                            88\    87\    87\    \< 0.001   0.904
                                                 ±36     ±28                      ±25                            ±27    ±26    ±26               

  HDL-C, mean ± SD \[mg/dl\]                     53\     56\                      57\                            58\    61\    56\    0.004      \< 0.001
                                                 ±17     ±18                      ±17                            ±17    ±17    ±17               

  Triglycerides, mean ± SD \[mg/dl\]             128\    88\                      89\                            83\    75\    77\    \< 0.001   0.004
                                                 ±78     ±49                      ±54                            ±51    ±46    ±36               

  Systolic blood pressure, mean ± SD \[mm Hg\]   124\    118\                     119\                           116\   114\   116\   \< 0.001   0.063
                                                 ±15     ±13                      ±13                            ±14    ±14    ±13               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

Treatment groups {#S20012}
----------------

Patients received comprehensive CVD risk intervention including diet and physical activity counseling and pharmacotherapy. Within the first year, pharmacotherapy was significantly increased. Statin use increased from 46% to 87%, niacin use from 16% to 68%, ezetimibe use from 5% to 15%, and ACEi use from 36% to 77% ([Figure 1](#F0001){ref-type="fig"}). Baseline treatment group categorizations are shown in [Table I](#T0001){ref-type="table"}.

![Prevalence of use of various pharmacologic therapies by year of follow-up](AMS-12-27875-g001){#F0001}

Lipid, HbA~1c~, hs-CRP, and blood pressure changes {#S20013}
--------------------------------------------------

There were statistically significant improvements in lipid parameters and systolic blood pressure during the first year of treatment, with stable trends afterwards ([Table II](#T0002){ref-type="table"}). LDL-C decreased by 25%, non-HDL-C decreased by 25%, triglycerides decreased by 31%, HDL-C increased by 6%, and systolic blood pressure decreased by 5% ([Table II](#T0002){ref-type="table"}, [Figure 2](#F0002){ref-type="fig"}). The mean and median HbA~1c~ value at baseline was 5.5%, with a standard deviation of 0.7%, interquartile range of 5.2% to 5.7%, and total range of 4.3% to 10.8%. There was not a significant association between HbA~1c~ and mean CIMT in a mixed model analysis over time. Mean hs-CRP at baseline was 1.1 mg/l, with a standard deviation of 2.3 mg/l, interquartile range of 0.5 mg/l to 2.1 mg/l, and total range of 0.1 mg/l to 15.7 mg/l. There was not a significant association between hs-CRP and mean CIMT in a mixed model analysis over time.

![Effect of comprehensive cardiovascular disease risk management on longitudinal changes in plaque type and cIMT changes in a community-based prevention clinic](AMS-12-27875-g002){#F0002}

CIMT findings {#S20014}
-------------

Statistically significant changes in CIMT and plaque composition occurred across all treatment groups ([Figure 3](#F0003){ref-type="fig"}). There was no statistically significant difference in CIMT between treatment groups. Average max CIMT at baseline was 1.86 mm, average mean CIMT was 0.77 mm, and average max-mean CIMT was 1.08 mm. After 1 year, max CIMT was 1.31 mm (30% regression), average mean CIMT was 0.73 mm (5% regression), and max-mean CIMT was 0.57 mm (47% regression), *p* \< 0.001. After 2 years, max CIMT was 0.88 mm (52% regression year-on-year) and max-mean CIMT was 0.14 mm (87% regression year-on-year), *p* \< 0.001 ([Table III](#T0003){ref-type="table"}). Mean CIMT continued to remain stable between 0.73 and 0.78 mm.

![CIMT parameters over follow-up](AMS-12-27875-g003){#F0003}

###### 

CIMT over follow-up

  -----------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                         Year    *P*-value (first year)   *P*-value (after first year)                                      
  --------------------------------- ------- ------------------------ ------------------------------ ------- ------- ------- ---------- ----------
  *N* (%)                           324\    280\                     234\                           167\    85\     20\                
                                    (100)   (86)                     (72)                           (52)    (26)    (6)                

  Mean CIMT, mean ± SD \[mm\]       0.77\   0.73\                    0.74\                          0.73\   0.75\   0.78\   \< 0.001   \< 0.001
                                    ±0.13   ±0.11                    ±0.12                          ±0.12   ±0.10   ±0.19              

  Max CIMT, mean ± SD \[mm\]        1.86\   1.31\                    0.88\                          0.83\   0.83\   0.88\   \< 0.001   \< 0.001
                                    ±1.04   ±0.86                    ±0.15                          ±0.14   ±0.11   ±0.20              

  Max-mean CIMT, mean ± SD \[mm\]   1.08\   0.57\                    0.14\                          0.10\   0.09\   0.10\   \< 0.001   \< 0.001
                                    ±1.00   ±0.84                    ±0.45                          ±0.04   ±0.03   ±0.03              

  Any plaque, *n* (%)               253\    209\                     172\                           117\    66\     15\     0.076      0.448
                                    (78)    (75)                     (74)                           (70)    (78)    (75)               

  Lipid-rich plaque, *n* (%)        172\    85\                      37\                            14\     2\      0\      \< 0.001   \< 0.001
                                    (53)    (30)                     (16)                           (8)     (2)     (0)                

  Heterogeneous plaque, *n* (%)     116\    158\                     126\                           85\     50\     10\     \< 0.001   0.714
                                    (36)    (56)                     (54)                           (51)    (59)    (50)               

  Calcified plaque, *n* (%)         56\     80\                      91\                            63\     35\     8\      \< 0.001   0.002
                                    (17)    (29)                     (39)                           (38)    (41)    (40)               
  -----------------------------------------------------------------------------------------------------------------------------------------------

Lipid-rich plaque, defined as echolucent plaque on ultrasonography, decreased by 50% the first year and 56% the second year, *p* \< 0.001. There was a 36% increase in heterogeneous plaque and a 43% increase in calcified plaque after the first year (*p* \< 0.001). There was no significant change in the amount of detectable plaque after the first year of starting treatment (*p* = 0.076) ([Table III](#T0003){ref-type="table"}).

Discussion {#S0015}
==========

The aim of this study was to longitudinally evaluate the effect of comprehensive CVD risk intervention on subclinical carotid atherosclerosis. Using serial B-mode ultrasonography, we observed significant regression of CIMT (max, max--mean) and lipid-rich plaque. Previous CIMT studies using statin therapy alone showed reduction in CIMT progression, not regression \[[@CIT0025]--[@CIT0028], [@CIT0030]\]. CIMT regression has been demonstrated in the setting of niacin monotherapy \[[@CIT0029]\] as well as in comprehensive CVD risk reduction therapy, although the latter was confounded by patients receiving carotid endarterectomies \[[@CIT0040]\]. Our study showed significant CIMT regression as well as regression of subclinical atherosclerotic plaque in response to a comprehensive treatment strategy with high prevalence of use of niacin in multiple drug combination therapy.

Studies using high-resolution computed tomography, magnetic resonance imaging, and B-mode ultrasonography found that aggressive lipid-lowering therapies stabilize plaque by promoting delipidation of vulnerable plaque \[[@CIT0032]--[@CIT0034], [@CIT0041], [@CIT0042]\]. These studies correlated decreasing plaque lucency on ultrasound with decreased lipid content of plaque. Compared with CT, ultrasonography offers advantages in research and clinical settings through lower cost and absence of ionizing radiation exposure.

Our study expands on the previously published CIMT studies by including a comprehensive diet, lifestyle, and intensive, multiple drug pharmacological intervention. There was a robust decrease in lipid-rich plaque during the first 2 years of treatment followed by a steady decline at later time points. Delipidation of subclinical plaque was associated with reductions in LDL-C and non-HDL-C, and was best explained by the summary effects of comprehensive behavioral and dietary prevention interventions in combination with statin-based lipid-lowering regimens directed toward reduction in non-HDL-C and LDL-C to target levels.

There are several limitations to this study. As a retrospective study, we encountered issues with incomplete clinical data such as family history, obesity, and duration of baseline medication use, which could cause residual confounding. Another limitation was retrospective grouping of treatment groups, which can introduce bias if groups are incorrectly assigned. The study population was composed of a self-selected group of motivated Caucasian patients, which may impact the generalizability of this study. We modeled our study to examine yearly changes in CIMT, plaque, and lipids based on the study design of prior clinical trials. There may be long-term effects on CIMT and plaque composition beyond the duration of our study that may be revealed with a larger population size with longer follow-up.

In conclusion, this study examined multi-year CIMT and plaque changes in a cohort of patients receiving comprehensive CVD risk intervention. Using serial imaging, we observed a reduction of lipid-rich plaques with a concurrent increase in heterogeneous and calcific plaques, suggesting regression of lipidrich plaque or transformation into heterogeneous and calcified forms. We believe that understanding the progression of subclinical atherosclerosis will help shape our approach to CVD prevention. These results show the beneficial effect of comprehensive, evidence-based lipid management on subclinical atherosclerosis and vulnerable plaque.
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